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Abstract
Background: Undifferentiated carcinoma (UC) of the liver is extremely rare, and its clinicopathological
characteristics have not been fully elucidated.
Case presentation: The present study reports the case of a 56-year-old male with UC of the liver. At 16 days
post-admission, the patient suddenly succumbed due to intra-abdominal bleeding resulting from a ruptured liver.
Macroscopic examination revealed that the hepatic parenchyma was almost completely replaced by innumerable
minute nodules. Microscopically, the tumor demonstrated a diffuse proliferation of anaplastic cells that were
positive for epithelial membrane antigen and neuron-specific enolase, suggesting neuroendocrine differentiation.
Grimelius and Fontana-Masson staining were negative. Neuroendocrine markers were also negative, including
chromogranin A, synaptophysin, and S-100 protein. Cytokeratin markers and mesenchymal markers were all
negative. Tumor markers, such as α-fetoprotein and carcinoembryonic antigen, were also negative.
Conclusions: Although larger studies involving more patients are required to establish a therapeutic strategy,
appropriate chemotherapy following an early diagnosis may be important to UC of the liver because the tumor
behaves in an aggressive way.
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Background
Undifferentiated carcinoma (UC) of the liver is an ex-
tremely rare malignant neoplasm [1, 2]. The clinicopath-
ological characteristics and clinical course of UC have
not been fully clarified, and a therapeutic strategy for
unresectable cases has not been established. The present
study reports the case of a 56-year-old male with UC of
the liver, together with the results of immunohistochem-
ical analysis.
Case presentation
A 56-year-old male with chronic hepatitis was admitted
due to hematemesis and general fatigue. The patient had
undergone a distal gastrectomy with Billroth I recon-
struction for duodenal ulcer 16 years previously. He had
no history of blood transfusion and alcohol abuse. Upon
physical examination, anemia, jaundice, and hepatomeg-
aly were noted. The laboratory findings upon admission
were as follows: hemoglobin, 10.8 g/dl; hematocrit,
32.4%; platelet count, 211 × 103/μl; white blood cell
count, 13.6 × 103/μl; serum total protein, 5.7 g/dl; serum
albumin, 3.2 g/dl; γ-globrin, 14.1%; total bilirubin,
2.7 mg/dl; serum aspartate aminotransferase, 150 IU/l;
serum alanine aminotransferase, 129 IU/l; serum
glutamyltransferase (γ-GT), 474 IU/l; serum alkaline
phosphatase (ALP), 833 IU/l; and NH3, 84 μg/dl. Viral
markers for hepatitis were negative, including hepatitis B
surface antigen and hepatitis C viral antibody. The α-
fetoprotein (AFP) was 3.8 ng/ml (normal range <20 ng/ml)
and PIVKA-II was normal (<0.06). A chest X-ray revealed
neither a mass lesion nor pleural effusion. Gastrointestinal
endoscopy revealed a hemorrhagic ulcer at the anasto-
mosis. Computed tomography revealed marked swelling of
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the liver and a hepatic parenchyma that was diffusely
rough (Fig. 1). It was difficult to distinguish tumorous area
from non-tumorous area because tumor margin was ob-
scurely demonstrated. A small amount of ascites was
found. Abdominal ultrasonography revealed a 6 × 6 cm iso-
echoic vague mass at the postero-inferior segment of the
liver. However, it was difficult to distinguish tumorous area
from non-tumorous area by also ultrasonography, and the
tumor seemed to spread through the whole liver. No ab-
normalities were demonstrated in the other organs, includ-
ing the gallbladder and pancreas. Therefore, this was
suspected to be a case of a diffuse type of hepatocellular
carcinoma, although an abdominal angiography could not
be performed due to the poor general status of the patient.
A fine-needle aspiration biopsy specimen of the liver
showed a diffuse proliferation of anaplastic cells with
hyperchromatic nuclei and scant cytoplasm, suggesting un-
differentiated carcinoma of the liver.
Following admission, the patient developed severe
hematemesis and the hemoglobin level decreased to
7.0 g/dl. Jaundice rapidly progressed, and the ascites in-
creased. At 16 days post-admission, the patient suddenly
succumbed due to intra-abdominal bleeding from a rup-
tured liver. On autopsy, the weight of the liver was
7.5 kg. The macroscopic examination revealed that the
hepatic parenchyma had almost totally been replaced by
innumerable minute nodules (Fig. 2). Microscopically, a
diffuse proliferation of anaplastic cells with hyperchro-
matic nuclei and scant cytoplasm was observed (Fig. 3),
indicating UC of the liver. In addition, mitotic figures
were frequently present.
Immunohistochemical studies were performed using
the avidin-biotin-peroxidase complex technique. Immu-
nopositivity was described as follows: (i) negative (−)
when <10% of the tumor cells were positive, (ii) focally
positive (1+) when 10–50% of the tumor cells were posi-
tive, and (iii) diffusely positive (2+) when >50% of the
tumor cells were positive. Tumor markers were negative,
including AFP, carcinoembryonic antigen, carbohydrate
antigen 19-9, and squamous cell carcinoma antigen,
whereas neuron-specific enolase (NSE) was focally posi-
tive (Fig. 4a). Epithelial membrane antigen was diffusely
Fig. 1 Computed tomography. The liver was remarkably swollen
and the parenchyma was diffusely rough
Fig. 2 Macroscopic finding. The hepatic parenchyma was almost
completely replaced by innumerable minute nodules
Fig. 3 Microscopic finding. a A diffuse proliferation of anaplastic
cells with hyperchromatic nuclei and scant cytoplasm, with frequent
mitotic figures. b Conspicuous portal venous invasion of the
tumor cells
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positive (Fig. 4b), whereas cytokeratin (CK) markers
(e.g., CK7, CK8, CK18, CK19, CK20, AE1/AE3, CAM
5.2, CK 902, and CK 903) were all negative. Grimelius
and Fontana-Masson staining were negative. Neuroen-
docrine markers were also negative, including chromo-
granin A, synaptophysin, and S-100 protein. Additional
mesenchymal markers were negative as well, such as
vimentin, desmin, α-smooth muscle actin, HHF-35, KP-1,
and CD34.
Discussion
UC of the liver is an extremely rare malignant neoplasm,
and its clinicopathological characteristics have not been
fully elucidated. Only a few case studies have been
published [1, 2] (Table 1). Nakasuka et al. [1] reported the
case of a patient with UC of the liver wherein a biopsy re-
vealed a UC pattern with neuroendocrine features. Immu-
nohistochemical analysis revealed immunoreactivity to the
synaptophysin endocrine marker. Additionally, the serum
NSE level was high at the time of diagnosis, although NSE
stain positivity was not specified. Therefore, the patient
was diagnosed with UC of the liver with neuroendocrine
features. Several immunohistochemical studies in primary
liver cancers with neuroendocrine differentiation have
been reported [3–7]. The World Health Organization
tumor classification states the synaptophysin and chromo-
granin A neuroendocrine markers are usually expressed in
high-grade neuroendocrine carcinoma [8]. Furthermore,
abnormal serum NSE and synaptophysin levels are con-
sidered to be additional evidence suggesting neuroendo-
crine differentiation.
Extrapulmonary small cell carcinomas are extremely
rare and can originate in a variety of sites, including the
liver, colon, stomach, esophagus, cervix, gallbladder, and
skin [9–14]. Zanconati et al. [9] reported three cases of
unusual small cell primary carcinoma of the liver. All
three tumors developed in non-cirrhotic livers and dem-
onstrated rapid clinical evolution, with mortality ensuing
between 1 and 5 months post-diagnosis. These tumors
were comprised of broad nests of small epithelial cells
positive for low-molecular weight keratins and AFP.
In the present case, the tumors were growing in a solid
nest comprising small cells with hyperchromatic nuclei
and scant cytoplasm, which indicated small cell carcin-
oma. By contrast, immunohistochemical analysis revealed
positive staining for NSE, although it was negative for
chromogranin A and synaptophysin, therefore suggesting
neuroendocrine differentiation. It is difficult to determine
which classification is appropriate for this type of tumor.
The tumor is referred to as UC with neuroendocrine fea-
tures, neuroendocrine carcinoma, or small cell carcinoma
of the liver. Thus, a novel entity of the tumor should be
established for the accumulation of such cases in the
future.
UC grows invasively, features a high incidence of me-
tastasis, and follows a rapid clinical course [2]. However,
no therapeutic strategies for unresectable tumors have
been established. Moertel et al. [15] reported the chemo-
therapeutic results for metastatic UC with endocrine fea-
tures and concluded that this type of tumor responded
Fig. 4 Immunohistochemical staining. a Neuron-specific enolase was
focally positive. b Epithelial membrane antigen was diffusely positive
Table 1 Summary of reported cases of undifferentiated hepatocellular carcinoma of the liver
Case Age Sex Tumor markers US/CT Immunohistochemistry Chemotherapy Prognosis
1. [1] 54 M WNL Multiple <3 cm Synaptophysin Etoposide + cisplatin Alive (8 m)
2. [2] 57 M WNL Solitary = 10 cm CAM5.2, HepPar1,
CK19, vimentin
Unknown Unknown
3. [Present case] 56 M WNL Diffuse NSE, EMA ND Died (16 days)
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strongly to etoposide and cisplatin regimen chemother-
apy. Similarly, Nakasuka et al. [1] reported a case of UC
of the liver with neuroendocrine features treated with
the same regimen that resulted in a positive clinical
course. Other studies reported poorly differentiated/
rapidly progressing neuroendocrine tumors [16] and
poorly differentiated neuroendocrine carcinoma of the
hepatobiliary tract and pancreas [17], which were treated
with a combination of cisplatin and etoposide.
Conclusions
We herein reported the case of a 56-year-old male with
UC of the liver. This tumor demonstrated a diffuse pro-
liferation of anaplastic cells, which were positive for NSE
suggesting neuroendocrine differentiation, and showed
an aggressive behavior. Therefore, appropriate chemo-
therapy following an early diagnosis may be important
to UC of the liver. In the future, larger studies on UC of
the liver should be conducted to analyze an appropriate
chemotherapeutic strategy for this rare disease.
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